You are here: Industry Insights > vertex

News List

Vertex fires COO Ian Smith for unspecified code of conduct violation fiercepharma
January 28, 2019
Vertex executive Ian Smith had only recently stepped into the company’s interim CFO role, which he held alongside his COO title. But now, Smith is leaving both positions following his behavior in violation of the company’s code of conduct.
Merck enters into an exclusive licensing agreement with Vertex biospectrumasia
January 28, 2019
Merck, a leading science and technology company has announced that it has entered into an exclusive licensing agreement with Vertex Pharmaceuticals Incorporated
Vertex sacks top exec, citing ‘personal behaviour’ pharmaphorum
January 25, 2019
Vertex has fired its chief operating officer and acting chief financial officer, Ian Smith, citing unspecified “personal behaviour” in breach of its code of conduct.
Vertex’s CF drug gets label extension as pricing row continues pharmaphorum
January 24, 2019
While UK cystic fibrosis patients continue their long wait for access to Vertex’s Orkambi, the drug has received a label extension from the European Commission allowing it to be used in younger children.
EC approves Vertex’s Orkambi for children with cystic fibrosis pharmaceutical-technology
January 23, 2019
Vertex Pharmaceuticals has received approval from the European Commission (EC) to expand the indication of its Orkambi to treat paediatric patients suffering from cystic fibrosis (CF)....
Vertex to submit Orkambi, Symkevi to SMC pharmatimes
December 21, 2018
Vertex has revealed that it will be submitting its cystic fibrosis medicines Orkambi and Symkevi to the Scottish Medicines Consortium for appraisal, following “constructive discussions” with the Scottish government.
Vertex wins European approval for new cystic fibrosis combination pharmaphorum
December 17, 2018
European regulators have approved Vertex’s new cystic fibrosis (CF) combination treatment Symkevi.The European Commission’s greenlight for Symkevi (tezacaftor/ivacaftor) will allow.....
Kalydeco approved by EU for CF in 12-14 month olds pharmatimes
November 30, 2018
Vertex Pharmaceuticals says the European Commission has granted approval of the label extension for Kalydeco, to include the treatment of patients with cystic fibrosis (CF) aged 12 to 24 months.
Vertex invests in Genomics plc as the firms sign research deal pharmatimes
November 26, 2018
UK analytics group Genomics plc has signed a three-year deal with Vertex centred on improving the discovery of targets for precision medicine, and has also raised £25 million to further expand its business.
EU approves Vertex’ cystic fibrosis combo pharmatimes
November 05, 2018
The European Commission has approved Vertex’ Symveki in a combination regimen with Kalydeco to treat certain patients with cystic fibrosis (CF)...

Previous page 1 2 3 4 5 6 7 Next page